PPBT stock forecast, quote, news & analysis

Key Takeaways

• Purple Biotech (PPBT) shares fell approximately 14% over the last 30 days, sliding from $1.70 on July 2, 2026, to $1.46 as of early August 2026.
• The stock's decline extends a broader quarterly rout that has seen PPBT lose roughly 65% of its value since early May 2026, when shares traded near $4.20.
• A pivotal single-day crash on June 11, 2026 — when shares plunged 48% on over 10.5 million shares traded — remains the dominant event shaping investor sentiment.
• Persistent dilution concerns, a low cash runway ($6.4 million as of March 31), a pending CEO transition, and a $200 million mixed shelf filing continue to weigh on the stock.
• While the company's CAPTN-3 tri-specific antibody platform has generated encouraging preclinical data, the market has yet to reward those developments without clear clinical or partnership catalysts.

Purple Biotech (PPBT) Company Overview and Market Position

Purple Biotech Ltd. (PPBT) is a clinical-stage oncology company headquartered in Rehovot, Israel, developing a next-generation immunotherapy platform known as CAPTN-3. The platform is built around masked tri-specific antibodies that simultaneously target tumor-associated antigens while engaging both T cells and natural killer (NK) cells. Its proprietary capping technology is designed to confine immune activation to the tumor microenvironment, aiming to expand the therapeutic window compared to conventional T-cell engagers. The lead candidate, IM1240, targets the 5T4 antigen and is advancing toward first-in-human clinical studies targeted for 2027. A second candidate, IM1305, targets TROP2 and remains in preclinical development. The company's earlier-stage assets — CM24 (a CEACAM1-blocking antibody) and NT219 (a dual IRS1/2 and STAT3 inhibitor) — are on hold pending partnership or additional investment, making CAPTN-3 the company's core value driver. With a market capitalization of approximately $6 million and a cash position expected to fund operations into 2027, PPBT is a speculative, high-risk biotech name closely watched by traders for binary catalysts.

Purple Biotech (PPBT) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 calendar days, PPBT stock declined approximately 14%, moving from a closing price of $1.70 on July 2, 2026, to $1.46 in early August trading. The stock tested a low of $1.33 on July 22 before briefly recovering to the $1.40–$1.50 range. Trading volumes remained elevated relative to the stock's thin pre-June float, with daily volume regularly exceeding 20,000 to 50,000 shares.

The quarterly performance paints an even starker picture. At the beginning of May 2026, PPBT traded around $4.20 per share. As of early August, the stock had lost roughly 65% of its value over that period. The most dramatic single-day move occurred on June 11, when shares crashed 48% — from $2.96 to $1.54 — on volume exceeding 10.5 million shares, following the company's presentation of preclinical data at the EACR 2026 Annual Congress. Since that session, PPBT has remained under sustained selling pressure, failing to mount any meaningful recovery.

What Drove PPBT Stock Price in the Last 30 Days

The stock's 14% decline over the past 30 days reflects a continuation of negative momentum that gathered force in June. Several verified factors contributed to the persistent downward pressure:

Continued fallout from the June 11 crash. The 48% single-day collapse on June 11 — the worst one-day drop in PPBT's recent history — was accompanied by a Weiss Ratings downgrade to "Sell (E)" and occurred despite the company presenting what it characterized as positive preclinical toxicology and efficacy data for IM1240. The enormous volume spike suggested large-scale institutional or insider selling, though no specific seller was publicly identified. The stock has not recovered, indicating that the market interpreted the event as a signal of deeper concerns.

Dilution overhang. A $200 million mixed securities shelf registration filed in the second quarter of 2026 remains an active concern for shareholders. With a market cap of roughly $6 million, any potential drawdown from this shelf would result in substantial dilution, creating a persistent ceiling on the stock.

Cash position and runway concerns. As of March 31, 2026, Purple Biotech held $6.4 million in cash and short-term deposits. While management estimates this provides a runway into 2027, the thin capital position leaves the company vulnerable to dilutive financing, particularly as it advances expensive preclinical programs toward human trials.

CEO transition. The March 2026 announcement that CEO Gil Efron would step down in August 2026 for health reasons, while remaining involved in corporate development, introduced leadership uncertainty at a critical juncture for the company. The ongoing search for a successor adds an additional layer of risk for investors.

Low liquidity and technical weakness. With a thinly traded float, even modest selling pressure can produce outsized price swings. The stock has consistently traded below its 20-day and 50-day moving averages, reinforcing a bearish technical picture.

What Drove PPBT Stock Performance Over the Last Quarter

The broader quarterly decline of approximately 65% reflects a convergence of structural, financial, and sentiment-driven headwinds. Following the 1-for-10 reverse ADS split in March 2026 — implemented to regain Nasdaq's $1.00 minimum bid price requirement — the stock initially traded at elevated post-split levels above $4.00. However, the reverse split did not resolve the underlying fundamental challenges.

The May 20 trading session marked the beginning of the multi-month slide, with shares falling from $3.51 to $2.98 on over 6.3 million shares traded. This appeared to coincide with warrant-related activity or early selling pressure linked to the shelf registration. The Q1 2026 earnings release on May 15, while highlighting encouraging IM1240 preclinical data and an expanded AI collaboration with Converge Bio, also reminded investors of the company's fragile balance sheet. The combination of a low cash balance, no near-term revenue, and an uncertain financing path created a difficult environment for sustained investor confidence. By the time of the EACR presentation in June, the stock had already lost roughly half its value from May levels. The June 11 crash merely accelerated a decline that was already well underway.

Trending AI Robots

In volatile market environments like the one surrounding PPBT, traders increasingly turn to data-driven tools for decision-making support. Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to navigate dynamic market conditions. Tickeron hosts hundreds of AI trading bots covering thousands of tickers across multiple strategies, timeframes, and performance profiles — but only the top-performing and most contextually relevant bots appear in this trending section. Each bot operates with a distinct strategy, ranging from short-term momentum plays to longer-duration swing trading approaches, allowing users to match automated strategies to their individual risk tolerance and market outlook. For investors seeking a systematic approach to stock selection and trade timing, exploring the Trending AI Robots page can provide actionable insight into what AI-driven models are signaling right now.

PPBT Stock Forecast Drivers: What Investors Should Watch Next

Several near-term catalysts and risks are likely to shape PPBT's trajectory in the months ahead. The appointment of a new CEO — expected by or shortly after August 2026 — will be closely scrutinized for strategic direction and capital allocation priorities. The company's next earnings report, anticipated in mid-August 2026, will provide an updated cash balance and guidance on the burn rate, both of which are critical given the current $6.4 million cushion. Any additional preclinical data releases for IM1240 or IM1305, particularly data that supports an Investigational New Drug (IND) filing, could serve as a positive catalyst. Conversely, any registered direct offering, at-the-market facility drawdown, or warrant exercise activity would likely pressure the stock further. The broader biotech funding environment and appetite for early-stage oncology names will also influence PPBT's ability to secure non-dilutive capital or partnership deals. Macroeconomic factors including interest rate expectations and risk-on/risk-off rotations in small-cap equities remain relevant background forces. All of these factors should be monitored carefully by investors evaluating the risk-reward profile of this early-stage immunotherapy developer.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations